Heart-lung Machine Market

Heart-lung Machine Market Summary

The global heart-lung machine market size was estimated at USD 2.24 billion in 2025 and is projected to reach USD 3.67 billion by 2033, growing at a CAGR of 6.36% from 2026 to 2033. The increasing burden of cardiovascular diseases, the rising number of open-heart surgeries, the adoption of technologically advanced perfusion systems, and the expansion of healthcare facilities in both emerging and developed regions are key aspects driving the market's growth.

In October 2025, Cleveland Clinic highlighted advances in ex vivo lung perfusion (EVLP), a perfusion-based system functionally aligned with heart-lung machine technologies, to assess and preserve donor lungs before transplantation.

The growth of heart and lung transplant programs is driving rising demand for advanced perfusion and extracorporeal support technologies, including heart-lung machines and associated consumables. In February 2025, the American Journal of Transplantation reported that U.S. adult heart transplants reached 4,092 in 2023, a 101.1% increase since 2012, with waitlist mortality falling to 8.5 deaths per 100 patient-years. Pediatric heart transplants also rose 36.3%, although the transplant rate declined 14.9%, and 5-year post-transplant survival rates were 80.3% for adults and 84.4% for children.In 2023, adult heart transplant rates varied by patient status, with Status 1 to 6 ranging from the highest urgency (Status 1) to the least urgent (Status 6), based on clinical condition and transplant need.

Collaboration between device manufacturers and hospitals is the prominent driver of growth in the heart-lung machine market, as it reduces the time from prototype to clinical use. Major manufacturers and specialist perfusion companies, such as LivaNova PLC and Getinge AB, conduct targeted clinical trials and regulatory programs in collaboration with cardiac centers to validate new cardiopulmonary bypass and ECMO platforms in real-world settings. Achieving regulatory milestones and generating early clinical data directly support broader procurement and hospital adoption. In December 2025, NHS Wales Shared Services Partnership entered into a service agreement with LivaNova UK Limited for the maintenance of heart-lung machines and autotransfusion systems supporting the Cardiothoracic Directorate at Cardiff & Vale University Health Board, covering the period from September 2025 to August 2026.

Moreover, the industry is undergoing significant change. These systems are essential for open-heart and complex thoracic procedures, while advances in surgical techniques, automation, and patient management are redefining their use. Hospitals and surgical centers are adopting new platforms that enhance clinical outcomes, reduce perfusion times, and minimize blood loss, supporting the shift toward precision-driven and minimally invasive cardiac care. In October 2025, Stanford Medicine expanded its minimally invasive coronary artery bypass grafting (CABG) program, which includes robotic-assisted and MIDCAB procedures, offering patients a faster recovery and reduced pain.

In addition, growing awareness and adoption of advanced cardiopulmonary bypass (CPB) techniques are driving the heart-lung machine market. Hospitals and cardiac centers are increasingly recognizing the benefits of modern CPB, which enables precise control of circulation and oxygenation during complex surgeries. This is prompting procurement of heart-lung machines with improved pumps, oxygenators, and integrated monitoring systems. The trend is particularly pronounced in tertiary and high-volume cardiac centers, which aim to enhance surgical efficiency and patient safety. In July-August 2025, a cross-sectional study in Iran reported high levels of awareness, attitude, and self-care behaviors among 138 post-CABG patients, highlighting that education and targeted nursing interventions significantly improve self-management and recovery outcomes.

Global Heart-Lung Machine Market Report Segmentation

This report forecasts revenue and volume growth at global, regional, and country levels and analyzes industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global heart-lung machine market report based on product, application, end use, and region:

• Product Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Capital Equipment
• Pumps
• Heater-Cooler Units / Heat Exchange Systems
• Monitoring Systems
• Others
• Consumables
• Cannulas
• By Product
• Arterial Cannulas
• Venous Cannulas
• Cardioplegia Cannulas
• Vent Cannulas
• ECMO Cannulas
• By Age Group
• Adult
• Pediatric
• Oxygenators
• By Product
• Membrane Oxygenators
• ECMO Oxygenators
• Pediatric/Neonatal Oxygenators
• Other Oxygenators
• By Age Group
• Adult
• Pediatric
• Blood Reservoirs & Filtration Systems
• Tubing Sets & Circuits
• Accessories & Consumables
• Application Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Coronary Artery Bypass Grafting (CABG)
• Heart Valve Surgeries
• Heart Transplant
• Lung Transplant
• Others
• End Use Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• Public Healthcare Institutions
• Private Healthcare Institutions
• Regional Outlook (Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• Spain
• Italy
• France
• Denmark
• Norway
• Sweden
• Asia Pacific
• Japan
• China
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Chile
• Colombia
• Argentina
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more